Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the 13 Best Japanese Stocks to Buy According to Hedge Funds. On ...

Takeda offers strong cash flow, solid growth in key areas, and a 4.4% yield, but trades at a premium despite its fundamentals ...

Discover why Takeda Pharmaceutical Company Limited remains a solid Buy. Click to explore TAK and its drug pipeline, growth ...

Japan’s largest pharma company Taked today announced that all primary and secondary endpoints were met in two Phase III ...

EU trade chief plans talks with US counterparts Monday Takeda ( TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, ...

Takeda’s oveporexton improved wakefulness, attention and other key narcolepsy endpoints “with a high degree of statistical significance,” according to Jefferies analysts.

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

Just as June began, Protagonist Therapeutics and Takeda Pharmaceutical Company Limited (NYSE: TAK) announced the full 32-week results from their Phase 3 VERIFY study of rusfertide in patients with ...

Takeda’s oral narcolepsy drug, oveporexton, has met the primary and secondary endpoints in two Phase III trials. The FirstLight (NCT06470828) and RadiantLight (NCT06505031) trials both met all their ...

Investing.com -- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK) stock rose 3.5% following the announcement of positive Phase 3 trial results for its investigational narcolepsy treatment oveporexton. The ...

Takeda Pharmaceutical ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating ...